Supportive Therapy in OncologySupportive Therapy in OncologyПоддерживающая терапия в онкологии3034-24733034-3178Publishing House ABV Press7710.17650/3034-2473-2026-3-1-12-29ORIGINAL REPORTSОРИГИНАЛЬНЫЕ СТАТЬИResearch ArticleProphylaxis and management of adverse events associated with datopotamab deruxtecanПрофилактика и лечение нежелательных явлений при терапии датопотамабом дерукстеканомhttps://orcid.org/0000-0003-1367-2079GladkovOleg A.ГладковОлег Александрович
Russian Federation
gladkovoa@gmail.comhttps://orcid.org/0000-0001-9749-8519ZhabinaAlbina S.ЖабинаА. С.
Russian Federation
gladkovoa@gmail.comhttps://orcid.org/0000-0003-4236-6476VladimirovaLyubov Yu.ВладимироваЛ. Ю.
Russian Federation
gladkovoa@gmail.comMedical center EVIMEDМедицинский центр «ЭВИМЕД»Saint Petersburg Clinical Research and Practical Centre for Specialized Types of Medical Care (Oncological)ГБУЗ «Санкт-Петербургский клинический научно-практический центр специализированных видов медицинской помощи (онкологический) им. Н.П. Напалкова»N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова»Минздрава РоссииNational Medical Research Centre for OncologyФГБУ «Национальный медицинский исследовательский центр онкологии» Минздрава России2606202631122914022026Copyright ©; 2026, ABV-PressCopyright ©; 2026, АБВ-пресс2026ABV-PressАБВ-прессhttps://creativecommons.org/licenses/by/4.0/https://stio.abvpress.ru/jour/article/view/77

Antibody-drug conjugates are a class of drugs designed to deliver highly effective cytostatic agents directly to tumor cells, thereby reducing their systemic effects and associated toxicity. One representative of this class is datopotamab deruxtecan (Dato-DXd), which is a conjugate of a monoclonal antibody with a cytostatic agent (topoisomerase I inhibitor) targeting trophoblast cell surface antigen 2 – a receptor widely expressed in non-small cell lung cancer, breast cancer and other solid tumors. Dato-DXd was first approved in Japan at the end of 2024 and then in the Russian Federation at the beginning of 2025. As is well known, the key to the successful use of any innovative drug is knowledge of its safety profile and management of adverse events. In this review, we present data on AEs observed in clinical trials of Dato-DXd, necessary preventive measures, and current recommendations for their diagnosis and treatment.

Конъюгаты моноклональных антител с лекарственным средством представляют собой класс препаратов, разработанных с целью доставки высокоэффективного цитостатика непосредственно в опухолевые клетки и тем самым снижения его системного воздействия и сопутствующей токсичности. Одним из представителей данного класса препаратов является датопотамаб дерукстекан (Dato-DXd), представляющий собой конъюгат моноклонального антитела с цитостатиком (ингибитором топоизомеразы I), направленного на поверхностный антиген клеток трофобласта 2 – рецептор, широко экспрессируемый при немелкоклеточном раке легкого, раке молочной железы и других солидных опухолях. Dato-DXd впервые был зарегистрирован в Японии в конце 2024 г. и далее в РФ в начале 2025 г. Как известно, залогом успеха применения любого инновационного препарата является знание его профиля безопасности и управления нежелательными явлениями. В данном обзоре мы приводим данные о нежелательных явлениях, наблюдаемых в клинических исследованиях Dato-DXd, необходимых мерах профилактики, а также текущие рекомендации по их диагностике и лечению.

monoclonal antibody-drug conjugatesdatopotamab deruxtecanadverse eventsinterstitial lung diseasestomatitiseye disordersконъюгаты моноклонального антитела с лекарственным средствомдатопотамаб дерукстеканнежелательное явлениеинтерстициальная болезнь легкихстоматитнарушение со стороны органа глазаMarei H.E., Cenciarelli C., Hasan A. Potential of antibody-drug conjugates (ADCs) for cancer therapy. Cancer Cell Int 2022;22:255. DOI: 10.1186/s12935-022-02679-8Dean A.Q., Luo S., Twomey J.D., Zhang B. Targeting cancer with antibody-drug conjugates: Promises and challenges. MAbs 2021;13:1951427. DOI:10.1080/19420862.2021.1951427General characteristics of the medicinal product DATROWAY (lyophilizate for the preparation of a concentrate for solution for infusion, 100 mg). Registration certificate: LP-№(008970)-(RG-RU)-210225 dated 21.02.2025 (reissued on 23.12.2025). Available at: https://storage.yandexcloud.net/sb-prod-astrazeneca-static-01/api/media/Datroway_OKhLP.pdf (In Russ.).Общая характеристика лекарственного препарата ДАТРОВЭЙ (лиофилизат для приготовления концентрата для приготовления раствора для инфузий, 100 мг). Регистрационное удостоверение: ЛП-№(008970)-(РГ-RU)-210225 от 21.02.2025 (переоформлено 3.12.2025). Доступно по:https://storage.yandexcloud.net/ sb-prod-astrazeneca-static-01/api/media/Datroway_OKhLP.pdfGeneral characteristics of the medicinal product ENHERTU (lyophilizate for the preparation of a concentrate for solution for infusion, 100 mg) 14.05.2024. Registration certificate: LP-№(001242)-(РГ-RU) 21.09.2022 (reissued on 12.10.2023). Available at: https://storage.yandexcloud.net/sb-prod-astrazeneca-static-01/api/media/Enhertu_OKhLP.pdf (In Russ.).Общая характеристика лекарственного препарата ЭНХЕРТУ (лиофилизат для приготовления концентрата для приготовления раствора для инфузий, 100 мг) от 14.05.2024. Регистрационное удостоверение: ЛП-№(001242)-(РГ-RU) от 21.09.2022 (переоформлено 12.10.2023). Доступно по: https://storage.yandexcloud.net/sb-prod-astrazeneca-static-01/api/media/Enhertu_OKhLP.pdfGeneral characteristics of the medicinal product KADCYLA (lyophilizate for the preparation of a concentrate for solution for infusion, 100 or 160 mg) 12.08.2025. Registration certificate: LP-№(000832)-(РГ-RU) 25.05.2022. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/ЛП-_N_000832_-_РГ-RU_/InstrImg_2025_09_12_1521359/5d1531f2-24cc-4cc7-8944-c403f7ca3c91.pdf (In Russ.).Общая характеристика лекарственного препарата КАДСИЛА (лиофилизат для приготовления концентрата для приготовления раствора для инфузий, 100 мг или 160 мг) от 12.08.2025. Регистрационное удостоверение: ЛП-№ ЛП-№(000832)-(РГ-RU) от 25.05.2022. Доступно по: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/ЛП-_N_000832_-_РГ-RU_/InstrImg_2025_09_12_1521359/5d1531f2-24cc-4cc7-8944-c403f7ca3c91.pdfNguyen T.D., Bordeau B.M., Balthasar J.P. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers (Basel) 2023;15(3):713. DOI: 10.3390/cancers15030713Suzuki Y., Zhou S., Ota Y. et al. Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis. JNCI Cancer Spectr 2023;7(5):pkad069. DOI: 10.1093/jncics/pkad069Inamura K., Yokouchi Y., Kobayashi M. et al. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. Oncotarget 2017;8:28725–35. DOI: 10.18632/ oncotarget.15647Sakach E., Sacks R., Kalinsky K. Trop-2 as a Therapeutic target in breast cancer. Cancers 2022;14:5936. DOI: 10.3390/cancers14235936Ambrogi F., Fornili M., Boracchi P. et al. Trop-2 is a determinant of breast cancer survival. PLoS One 2014;9:e96993. DOI: 10.1371/journal.pone.0096993Okajima D., Yasuda S., Maejima T. et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther 2021;20:2329–40. DOI: 10.1158/1535-7163.Mct-21-0206Shimizu T., Sands J., Yoh K. et al. First-in-human, phase i dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01. J Clin Oncol 2023;41:4678–87. DOI: 10.1200/JCO.23.00059Ahn M.J., Lisberg A., Goto Y. et al. A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC. J Thorac Oncol 2025;20(11):1669–82. DOI: 10.1016/j.jtho.2025.06.002Bardia A., Jhaveri K., Im S.A. et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol 2025;43(3):285–96. DOI: 10.1200/JCO.24.00920Pistilli B., Jhaveri K., Im S.A. et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study. Ann Oncol 2025:S0923-7534(25)06337-9. DOI: 10.1016/j.annonc.2025.12.017Dent R., Shao Z., Schmid P. et al. [oral presentation]. First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase 3 TROPION-Breast02 trial. Presented at: European Society of Medical Oncology Annual Meeting; October 17–21, 2025; Berlin, Germany; Abstract LBA21.A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I–III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03). ClinicalTrials.gov; 2026 [updated December 19, 2025; quoted February 4, 2026]. Available at: https://clinicaltrials.gov/study/NCT05629585.Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07). ClinicalTrials.gov; 2026 [updated January 12, 2025; quoted February 4, 2026]. Available at: https://clinicaltrials.gov/study/NCT05555732Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08). ClinicalTrials.gov; 2026 [updated January 7, 2026; quoted on February 4, 2026]. Available at: https://clinicaltrials.gov/study/NCT05215340Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03). ClinicalTrials.gov; 2026 [updated July 11, 2025; quoted February 4, 2026]. Available at: https://clinicaltrials.gov/study/NCT05489211Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR). ClinicalTrials.gov; 2026 [updated December 10, 2025; quoted February 4, 2026]. Available at: https://clinicaltrials.gov/study/NCT05687266Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14). ClinicalTrials.gov; 2026 [updated November 17, 2025; quoted February 4, 2026]. Available at: https://clinicaltrials.gov/study/NCT06350097.A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung15). ClinicalTrials.gov; 2026 [updated January 9, 2026; quoted February 4, 2026]. Available at: https://clinicaltrials.gov/study/NCT06417814Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma. ClinicalTrials.gov; 2026 [updated January 30, 2026; quoted February 4, 2026]. Available at: https://clinicaltrials.gov/study/NCT07129993?intr=datopotamab%20deruxtecan&aggFilters=phase:3&rank=4Huang J., Huang T., Guo J. et al. The efficacy and safety of datopotamab deruxtecan (Dato-DXd) in advanced solid tumors: a systematic review and meta-analysis. Eur J Med Res 2025;30(1):1265. DOI: 10.1186/s40001-025-03538-8Brown T.J., Gupta A. Management of cancer therapy-associated oral mucositis. JCO Oncol Pract 2020;16:103–19. DOI: 10.1200/JOP.19.00652Basile D., Di Nardo P., Corvaja C. et al. Mucosal injury during anti-cancer treatment: from pathobiology to bedside. Cancers (Basel) 2019;11(6):857. DOI: 10.3390/cancers11060857Lu Y., Patel K., Li H. et al. Exposure-response analysis of stomatitis associated with Datopotamab Deruxtecan, a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancer [Poster W-001] American Conference on Pharmacometrics, 2023.Heist R.S., Sands J., Bardia A. et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. DOI: 10.1016/j.ctrv.2024.102720A Phase 3, Open-label, Randomized Study of Dato-DXd Versus Investigator’s Choice of Chemotherapy in Participants with Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Who Have Been Treated with One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01): Clinical Study Protocol. Version 5.0. AstraZeneca; 2023. Available at: https://s3.amazonaws.com/ctr-med-7111/D9268C00001/1ad6cc6b-d845-4b62-8243-638bb9d24742/b9df981b-dd52-4380-b847-3f8b1ae10f10/CSP_redacted-v1.pdfPhase 3 Randomized Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-Lung01): Clinical Study Protocol. Version 5.0. Daiichi Sankyo. Inc.; 2023. Access date: 08.12.2025. Available at: https://ascopubs.org/action/downloadSupplement?doi=10.1200%2FJCO-24-01544&file=protocol_JCO-24-01544.pdfLisberg A., Huppert L.A., Halmos B. et al. Datopotamab deruxtecan-associated select adverse events: clinical practices and institutional protocols on prophylaxis, monitoring, and management. Oncologist 2025;30(9):oyaf225. DOI: 10.1093/oncolo/oyaf225National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ docs/CTCAE_v5_Quick_Reference_8.5x11.pdfSemiglazova T.Yu., Belyak N.P., Vladimirova L.Yu. et al. Mucositis. RUSSCO Clinical Guidelines, Part 2. Zlokachestvennye opukholi = Malignant Tumours 2025;15(3s2):352–64. DOI: 10.18027/2224-5057-2025-15-3s2-2-18Семиглазова Т.Ю., Беляк Н.П., Владимирова Л.Ю. и др. Мукозиты. Клинические рекомендации RUSSCO, ч. 2. Злокачественные опухоли 2025;15(3s2):352–64. (In Russ.). DOI: 10.18027/2224-5057-2025-15-3s2-2-18Bader A., Begemann M., Al-Obaidi A. et al. Ocular complications of antineoplastic therapies. Future Sci OA 2023;9:FSO871. DOI: 10.2144/fsoa-2022-0081Eaton J.S., Miller P.E., Mannis M.J., Murphy C.J. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther 2015;31:589–604. DOI: 10.1089/jop.2015.0064American Optometric Association. Dry eye. Aoa.org; 2026.[updated January 12, 2026; quoted February 4, 2026]. Available at: https://www.aoa.org/healthy-eyes/eye-and-vision-conditions/ dry-eye?sso=yAmerican Optometric Association. Keratitis. Aoa.org; 2026. [updated January 12, 2026; quoted February 4, 2026]. Available at: https://www.aoa.org/healthy-eyes/eye-and-vision-conditions/keratitis?sso=yMessmer E.M. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int 2015;112:71–81. DOI: 10.3238/arztebl.2015.0071Renouf D.J., Velazquez-Martin J.P. et al. Ocular toxicity of targeted therapies. J Clin Oncol 2012;30:3277–86. DOI:10.1200/ JCO.2011.41.5851Tarantino P., Ricciuti B., Pradhan S.M., Tolaney S.M. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol 2023;20:558–76. DOI:10.1038/s41571-023-00783-wStepan L.P., Trueblood E.S., Hale K. et al. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem 2011;59:701–10. DOI: 10.1369/0022155411410430Girard N., Okamoto I., Lisberg A. et al. Datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC) – nonsquamous (NSQ) histology in the Phase 3 TROPION-Lung01 trial. Poster presented at: European Lung Cancer Congress; March 20–23, 2024; Prague, Czech Republic.Jhaveri K., Bardia A., Im S.-A. et al. LBA2 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in pretreated, inoperable/metastatic HR+/HER2– breast cancer (BC): additional safety analysis from TROPION-Breast01. ESMO Open 2024;9:103479. DOI: 10.1016/j.esmoop.2024.103479Conte P., Ascierto P.A., Patelli G. et al. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open 2022;7:100404. DOI: 10.1016/j.esmoop.2022.100404Long K., Suresh K. Pulmonary toxicity of systemic lung cancer therapy. Respirology 2020;25(Suppl 2):72–9. DOI: 10.1111/resp.13915Swain S.M., Nishino M., Lancaster L.H. et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd) – related interstitial lung disease/pneumonitis – Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev 2022;106:102378. DOI: 10.1016/j. ctrv.2022.102378Muller N.L., White D.A., Jiang H., Gemma A. Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer 2004;91(Suppl 2):24–30. DOI: 10.1038/sj.bjc.6602064Kumagai K., Aida T., Tsuchiya Y. et al. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci 2020;111:4636–45. DOI: 10.1111/cas.14686Cereser L., Della Rossa S., Sparascio F. et al. Chest computed tomography of trastuzumab-deruxtecan (T-DXd)-related interstitial lung disease: Key points for radiologists. Eur J Radiol 2026;194:112499. DOI: 10.1016/j.ejrad.2025.112499Zhabina A. S., Trushenko N. V., Tyurin I. E. et al. Drug-induced interstitial lung diseases. RUSSCO clinical guidelines, part 2. Zlokachestvennye opukholi = Malignant tumours 2025;15(3s2): 330–51. (In Russ.). DOI: 10.18027/2224-5057-2025-15-3s2-2-17Жабина А.С., Трушенко Н.В., Тюрин И.Е. и др. Лекарственно индуцированные интерстициальные болезни легких. Клинические рекомендации RUSSCO, ч. 2. Злокачественные опухоли 2025;15(3s2):330–51. DOI: 10.18027/2224-5057-2025-15-3s2-2-17Vladimirova L.Yu., Gladkov O.A., Koroleva I.A. et al. Nausea and vomiting. RUSSCO clinical guidelines, part 2. Zlokachestvennye opukholi = Malignant tumours 2025;15(3s2): 33–49. (In Russ.). DOI: 10.18027/2224-5057-2025-15-3s2-2-02Владимирова Л.Ю., Гладков О.А., Королева И.А. и др. Тошнота и рвота. Клинические рекомендации RUSSCO, ч. 2. Злокачественные опухоли 2025;15(3s2):33–49. DOI: 10.18027/2224-5057-2025-15-3s2-2-02NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Antiemesis. Version: 2.2025. Updated on May 12, 2025. Available at: https://www.nccn.org/professionals/ physician_gls/pdf/antiemesis.pdfRombouts M.D., Swart E.L., VAN DEN Eertwegh A.J.M., Crul M. Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment. Anticancer Res 2020;40:1201–18. DOI: 10.21873/ anticanres.14062Rosello S., Blasco I., Garcia Fabregat L. et al. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. Ann Oncol 2017;28(suppl_4):iv100–18. DOI: 10.1093/ annonc/mdx216Thompson L.M., Eckmann K., Boster B.L. et al. Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab. Oncologist 2014;19:228–34. DOI: 10.1634/theoncologist.2013-0286Horita N., Miyagi E., Mizushima T. et al. Severe anaphylaxis caused by intravenous anti-cancer drugs. Cancer Med 2021;10:7174–83. DOI: 10.1002/cam4.4252Lemieux J., Maunsell E., Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology 2008;17:317–28. DOI: 10.1002/pon.1245Ahn M.J., Tanaka K., Paz-Ares L. et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol 2025;43(3):260–72. DOI: 10.1200/JCO-24-01544Prieto-Callejero B., Rivera F., Fagundo-Rivera J. et al. Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer. Medicine (Baltimore) 2020;99:e21695. DOI: 10.1097/MD.0000000000021695Ho M.Y., Mackey J.R. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res 2014;6:253–9. DOI: 10.2147/CMAR.S40601Latipova D.Kh., Andreev V.V., Maslova D.A. et al. Neurological complications. RUSSCO clinical guidelines, part 2. Zlokachestvennye opukholi = Malignant tumours 2025;15(3s2): 410–25. (In Russ.). DOI: 10.18027/2224-5057-2025-15-3s2-2-22Латипова Д.Х., Андреев В.В., Маслова Д.А. и др. Неврологические осложнения. Клинические рекомендации RUSSCO, ч. 2. Злокачественные опухоли 2025;15(3s2):410–25. DOI: 10.18027/2224-5057-2025-15-3s2-2-22